ENXTPA:IPNPharmaceuticals
Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?
Key Insights The projected fair value for Ipsen is €178 based on 2 Stage Free Cash Flow to Equity Current share price...
ENXTPA:EAPIPharmaceuticals
Euroapi S.A.'s (EPA:EAPI) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Euroapi's (EPA:EAPI) stock is up by a considerable 16% over the past three months. We wonder if and what role the...
ENXTPA:VIRPPharmaceuticals
Is There An Opportunity With Virbac SA's (EPA:VIRP) 40% Undervaluation?
Key Insights Virbac's estimated fair value is €411 based on 2 Stage Free Cash Flow to Equity Current share price of...
ENXTPA:VETOPharmaceuticals
Is Vetoquinol SA (EPA:VETO) Trading At A 45% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vetoquinol fair value estimate is €148 Vetoquinol's €81.10...
ENXTPA:IPNPharmaceuticals
These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
ENXTPA:VIRPPharmaceuticals
Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
ENXTPA:SANPharmaceuticals
Is Sanofi's (EPA:SAN) Recent Performance Tethered To Its Attractive Financial Prospects?
Sanofi's (EPA:SAN) stock is up by 5.0% over the past month. Given that the market rewards strong financials in the...
ENXTPA:EAPIPharmaceuticals
Euroapi S.A.'s (EPA:EAPI) market cap surged €56m last week, public companies who have a lot riding on the company were rewarded
Key Insights Significant control over Euroapi by public companies implies that the general public has more power to...
ENXTPA:BOIPharmaceuticals
Boiron SA (EPA:BOI) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Boiron's (EPA:BOI) stock is up by a considerable 38% over the past three months. However, we decided to pay attention...
ENXTPA:IPNPharmaceuticals
Ipsen S.A. (EPA:IPN) most popular amongst private companies who own 31%, insiders hold 27%
Key Insights The considerable ownership by private companies in Ipsen indicates that they collectively have a greater...
ENXTPA:VIRPPharmaceuticals
Investing in Virbac (EPA:VIRP) five years ago would have delivered you a 119% gain
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a...
ENXTPA:SANPharmaceuticals
Is There An Opportunity With Sanofi's (EPA:SAN) 47% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Sanofi fair value estimate is €177 Current share price of...
ENXTPA:MEDCLPharmaceuticals
Individual investors who hold 53% of MedinCell S.A. (EPA:MEDCL) gained 13%, institutions profited as well
Key Insights MedinCell's significant individual investors ownership suggests that the key decisions are influenced by...
ENXTPA:EAPIPharmaceuticals
Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results
It's been a good week for Euroapi S.A. ( EPA:EAPI ) shareholders, because the company has just released its latest...
ENXTPA:EAPIPharmaceuticals
Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €24.50 Euroapi is estimated to...
ENXTPA:IPNPharmaceuticals
Is Ipsen S.A.'s (EPA:IPN) Stock's Recent Performance A Reflection Of Its Financial Health?
Most readers would already know that Ipsen's (EPA:IPN) stock increased by 4.6% over the past three months. Since the...
ENXTPA:VETOPharmaceuticals
Vetoquinol's (EPA:VETO) 12% CAGR outpaced the company's earnings growth over the same five-year period
When we invest, we're generally looking for stocks that outperform the market average. And in our experience, buying...
ENXTPA:VIRPPharmaceuticals
Insiders the biggest winners as Virbac SA's (EPA:VIRP) market cap rises to €2.4b
Key Insights Virbac's significant insider ownership suggests inherent interests in company's expansion A total of 2...
ENXTPA:SANPharmaceuticals
Sanofi (EPA:SAN) jumps 5.5% this week, though earnings growth is still tracking behind five-year shareholder returns
If you want to compound wealth in the stock market, you can do so by buying an index fund. But the truth is, you can...
ENXTPA:IPNPharmaceuticals
Those who invested in Ipsen (EPA:IPN) three years ago are up 42%
Low-cost index funds make it easy to achieve average market returns. But if you invest in individual stocks, some are...
ENXTPA:VIRPPharmaceuticals
Is Weakness In Virbac SA (EPA:VIRP) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
With its stock down 16% over the past month, it is easy to disregard Virbac (EPA:VIRP). However, a closer look at its...
ENXTPA:BOIPharmaceuticals
Boiron's (EPA:BOI) earnings trajectory could turn positive as the stock soars 30% this past week
This month, we saw the Boiron SA ( EPA:BOI ) up an impressive 33%. But over the last half decade, the stock has not...
ENXTPA:VETOPharmaceuticals
Is Vetoquinol SA's (EPA:VETO) Latest Stock Performance Being Led By Its Strong Fundamentals?
Vetoquinol's (EPA:VETO) stock up by 7.3% over the past three months. Given that the market rewards strong financials in...
ENXTPA:SANPharmaceuticals
With 57% ownership of the shares, Sanofi (EPA:SAN) is heavily dominated by institutional owners
Key Insights Given the large stake in the stock by institutions, Sanofi's stock price might be vulnerable to their...